Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses.

Adult Aged Antineoplastic Combined Chemotherapy Protocols / adverse effects Breast Neoplasms / drug therapy Female Humans Middle Aged Response Evaluation Criteria in Solid Tumors Retrospective Studies Sarcoma / pathology
Advanced setting Breast tumor Chemotherapy Phyllodes Sarcoma

Journal

Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104

Informations de publication

Date de publication:
Apr 2022
Historique:
received: 02 10 2021
accepted: 16 01 2022
pubmed: 13 2 2022
medline: 31 3 2022
entrez: 12 2 2022
Statut: ppublish

Résumé

We aimed at investigating outcome of systemic treatments in advanced breast PT. All cases of advanced breast PT treated with systemic treatments from 1999 to 2019, in one of the referral sarcoma centers involved in the study, were retrospectively reviewed. 56 female patients were identified. Median age was 52 (range of 25-76) years. Patients received a median number of 2 systemic treatments (range of 1-4). Best responses according to RECIST were 1 (3.7%) CR, 11 (40.7%) PR, 6 (22.2%) SD, 9 (33.3%) PD with anthracyclines plus ifosfamide (AI); 2 (16.7%) PR, 4 (33.3%) SD, 6 (50.0%) PD with anthracycline alone; 3 (18.8%) PR, 4 (25.0%) SD, 9 (56.3%) PD with high-dose ifosfamide given as a continuous infusion (HD-IFX); 3 (20.0%) SD, 12 (80.0%) PD with a gemcitabine-based regimen (with 2 patients not evaluable); 1 (8.3%) PR, 2 (16.7%) SD, 9 (75.0%) PD with trabectedin (with 1 patient not evaluable); 1 (16.7%) PR, 1 (16.7%) SD, 4 (66.7%) PD with tyrosine-kinase inhibitors (TKI). The median PFS were 5.7 (IQR 2.5-9.1) months with AI; 3.2 (IQR 2.2-5.0) months with anthracycline alone; 3.4 (IQR 1.4-6.7) months with HD-IFX; 2.1 (IQR 1.4-5.2) months with gemcitabine-based chemotherapy; 1.8 (IQR 0.7-6.6) months with trabectedin; 3.4 (IQR 3.1-3.8) months with TKI. With a median follow-up of 35.3 (IQR 17.6-66.9) months, OS from the start of first-line systemic treatment was 15.2 (IQR 7.6-39.6) months. In this series of advanced PT (to our knowledge, the largest reported so far), AI was associated with a high rate of responses, however, with a median PFS of 5.7 months. Other systemic treatments were poorly active.

Sections du résumé

BACKGROUND BACKGROUND
We aimed at investigating outcome of systemic treatments in advanced breast PT.
METHODS METHODS
All cases of advanced breast PT treated with systemic treatments from 1999 to 2019, in one of the referral sarcoma centers involved in the study, were retrospectively reviewed.
RESULTS RESULTS
56 female patients were identified. Median age was 52 (range of 25-76) years. Patients received a median number of 2 systemic treatments (range of 1-4). Best responses according to RECIST were 1 (3.7%) CR, 11 (40.7%) PR, 6 (22.2%) SD, 9 (33.3%) PD with anthracyclines plus ifosfamide (AI); 2 (16.7%) PR, 4 (33.3%) SD, 6 (50.0%) PD with anthracycline alone; 3 (18.8%) PR, 4 (25.0%) SD, 9 (56.3%) PD with high-dose ifosfamide given as a continuous infusion (HD-IFX); 3 (20.0%) SD, 12 (80.0%) PD with a gemcitabine-based regimen (with 2 patients not evaluable); 1 (8.3%) PR, 2 (16.7%) SD, 9 (75.0%) PD with trabectedin (with 1 patient not evaluable); 1 (16.7%) PR, 1 (16.7%) SD, 4 (66.7%) PD with tyrosine-kinase inhibitors (TKI). The median PFS were 5.7 (IQR 2.5-9.1) months with AI; 3.2 (IQR 2.2-5.0) months with anthracycline alone; 3.4 (IQR 1.4-6.7) months with HD-IFX; 2.1 (IQR 1.4-5.2) months with gemcitabine-based chemotherapy; 1.8 (IQR 0.7-6.6) months with trabectedin; 3.4 (IQR 3.1-3.8) months with TKI. With a median follow-up of 35.3 (IQR 17.6-66.9) months, OS from the start of first-line systemic treatment was 15.2 (IQR 7.6-39.6) months.
CONCLUSION CONCLUSIONS
In this series of advanced PT (to our knowledge, the largest reported so far), AI was associated with a high rate of responses, however, with a median PFS of 5.7 months. Other systemic treatments were poorly active.

Identifiants

DOI: 10.1007/s10549-022-06524-4 PMID: 35150367
pubmed: 35150367
doi: 10.1007/s10549-022-06524-4
pii: 10.1007/s10549-022-06524-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

603-610

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Tan PH, TSe G, Koo JS et al (2019) Fibroepithelial tumours. WHO classification of tumours of the breast. Lyon 172–176
Zhang Y, Kleer CG (2016) Phyllodes tumor of the breast: histopathologic features, differential diagnosis, and molecular/genetic updates. Arch Pathol Lab Med 140(7):665–671
doi: 10.5858/arpa.2016-0042-RA
Telli ML, Horst KC, Guardino AE et al (2007) Phyllodes tumors of the breast: natural history, diagnosis, and treatment. J Natl Compr Canc Netw 5(3):324–330
doi: 10.6004/jnccn.2007.0027
Spitaleri G, Toesca A, Botteri E et al (2013) Breast phyllodes tumor: a review of literature and a single center retrospective series analysis. Crit Rev Oncol Hematol 88(2):427–436
doi: 10.1016/j.critrevonc.2013.06.005
Neron M, Sajous C, Thezenas S et al (2020) French Sarcoma Group (GSF-GETO). Impact of metastasis surgery and alkylating-agent-based chemotherapy on outcomes of metastatic malignant phyllodes tumors: a multicenter retrospective study. Ann Surg Oncol. 27(5):1693–1699
doi: 10.1245/s10434-019-08097-x
Mituś JW, Blecharz P, Walasek T et al (2016) Treatment of patients with distant metastases from phyllodes tumor of the breast. World J Surg 40(2):323–328
doi: 10.1007/s00268-015-3262-7
Ramakant P, Therese MM et al (2015) Metastatic malignant phyllodes tumor of the breast: an aggressive disease-analysis of 7 cases. Indian J Surg Oncol. 6(4):363–9
doi: 10.1007/s13193-015-0397-9
Parkes A, Wang WL, Patel S et al (2021) Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Res Treat 186(3):871–882
doi: 10.1007/s10549-021-06116-8
CTEP.Cancer.gov [homepage on the internet]. Bethesda: NCI; [updated 2017 Nov 27]. http://ctep.cancer.gov/protocol/Development/electronic_applications/ctc.htm#ctc_50 .
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247
doi: 10.1016/j.ejca.2008.10.026
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53(282):457–481
doi: 10.1080/01621459.1958.10501452
Judson I, Verweij J, Gelderblom H et al (2014) European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 15(4):415–23
doi: 10.1016/S1470-2045(14)70063-4
Grignani G, D’Ambrosio L, Pignochino Y et al (2018) Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. Lancet Oncol 19(10):1360–1371
doi: 10.1016/S1470-2045(18)30438-8
Park IH, Kwon Y, Kim EA et al (2009) Major response to sunitinib (Sutene) in metastatic malignant phyllodes tumor of breast. Invest New Drugs 27(4):387–388
doi: 10.1007/s10637-008-9195-3
Casali PG, Abecassis N, Aro HT et al (2018) ESMO Guidelines Committee and EURACAN. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:268–269
doi: 10.1093/annonc/mdy321
Cani AK, Hovelson DH, McDaniel AS et al (2015) Next-gen sequencing exposes frequent MED12 mutations and actionable therapeutic targets in phyllodes tumors. Mol Cancer Res 13(4):613–619
doi: 10.1158/1541-7786.MCR-14-0578
Liu SY, Joseph NM, Ravindranathan A et al (2016) Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. Mod Pathol 29(9):1012–1027
doi: 10.1038/modpathol.2016.97
Piscuoglio S, Geyer FC, Burke KA et al (2016) Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor. NPJ Breast Cancer 2:16035
doi: 10.1038/npjbcancer.2016.35
Nozad S, Sheehan CE, Gay LM et al (2017) Comprehensive genomic profiling of malignant phyllodes tumors of the breast. Breast Cancer Res Treat 162(3):597–602
doi: 10.1007/s10549-017-4156-1

Auteurs

E Palassini (E)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. elena.palassini@istitutotumori.mi.it.
ORCID: 0000-0003-2257-4681

O Mir (O)

Department of Ambulatory Cancer Care, Sarcoma Group, Gustave Roussy, Villejuif, France.

G Grignani (G)

Division of Medical Oncology, Candiolo Cancer Institute, FPO - IRCCS, Candiolo, TO, Italy.

B Vincenzi (B)

Department of Medical Oncology, Campus Biomedico University, Rome, Italy.

H Gelderblom (H)

Department of Medical Oncology, LUMC - Leiden University Medical Center, Leiden, Netherlands.

A Sebio (A)

Hospital Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.

C Valverde (C)

Vall d'Hebron University Hospital, Barcelona, Spain.

G G Baldi (GG)

Department of Medical Oncology, Ospedale "Santo Stefano", Prato, Italy.

A Brunello (A)

Department of Oncology, Oncology 1 Unit, Istituto Oncologico Veneto - IOV, IRCCS, Padua, Italy.

G G Cardellino (GG)

Department of Oncology, Presidio "S. Maria della Misericordia" di Udine, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.

A Marrari (A)

Department of Oncology and Hematology, Humanitas Cancer Center Rozzano, Rozzano, Milan, Italy.

G Badalamenti (G)

Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy.

J Martin-Broto (J)

Fundación Jiménez Díaz University Hospital, Madrid, Spain.

V Ferraresi (V)

Sarcomas and Rare Tumors Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

M Libertini (M)

Department of Oncology, Fondazione Poliambulanza, Brescia, Italy.

S Turano (S)

Department of Oncology, Azienda Ospedaliera di Cosenza, Cosenza, Italy.

I Gataa (I)

Department of Ambulatory Cancer Care, Sarcoma Group, Gustave Roussy, Villejuif, France.

P Collini (P)

Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

A P Dei Tos (APD)

Department of Pathology, Azienda Ospedaliera Università Padova, Padua, Italy.

M Gennaro (M)

Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

F Bini (F)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

S Provenzano (S)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

S Lo Vullo (SL)

Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

L Mariani (L)

Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

A Le Cesne (A)

Department of Ambulatory Cancer Care, Sarcoma Group, Gustave Roussy, Villejuif, France.

P G Casali (PG)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Systemic treatment in advanced phyllodes tumor...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Systemic treatment in advanced phyllodes tumor...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Systemic treatment in advanced phyllodes tumor...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Systemic treatment in advanced phyllodes tumor...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Systemic treatment in advanced phyllodes tumor...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Systemic treatment in advanced phyllodes tumor...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Évaluation de la réponse des tumeurs solides aux traitements › Systemic treatment in advanced phyllodes tumor...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Systemic treatment in advanced phyllodes tumor...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu conjonctif et des tissus mous › Sarcomes › Systemic treatment in advanced phyllodes tumor...